Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bosc
Christophe Bosc, Grenoble FR
| Patent application number | Description | Published |
|---|---|---|
| 20090064353 | Transgenic or recombinant non-human mammals and their uses in screening psychoactive medicines - The invention concerns transgenic or recombinant non-human mammals, wherein the expression of the gene coding for a microtubule associated protein (MAP) is modified (STOP gene) (inactivation or overexpression) and their uses in screening medicines useful in schizophrenia and schizo-affective disorders, with anxious, paranoiac or depressive component. | 03-05-2009 |
Denis Bosc, Winnipeg CA
| Patent application number | Description | Published |
|---|---|---|
| 20090220934 | METHODS AND PROCESSES OF CONTROLLING FERMENTATION - The present invention relates to methods and processes for controlling fermentation. Two proportional feedback control loops are implemented in a cascade. One control loop is used to maintain the pH by adjusting the dissolved oxygen-stat setpoint. The other control loop is used to maintain the dissolved oxygen by regulating the nutrient feed rate using the newly adjusted dissolved oxygen-set point. | 09-03-2009 |
Denis Georges Bosc, Manitoba CA
| Patent application number | Description | Published |
|---|---|---|
| 20080219994 | MODIFIED BOUGANIN PROTEINS, CYTOTOXINS AND METHODS AND USES THEREOF - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 09-11-2008 |
| 20100254964 | Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 10-07-2010 |
Emilie Bosc, Fontenay-Aux-Roses FR
| Patent application number | Description | Published |
|---|---|---|
| 20110109904 | Method and Device for High Speed Quantitative Measurement of Biomolecular Targets on or in Biological Analysis Medium - The present invention relates to a device and method for the high speed quantitative measurement of biomolecular targets on the surface or in the body of a planar medium for biological analysis. The method, according to the invention, includes the following, steps: a) at least two laser beams (F″) are focused and overlaid on each measuring point of said medium by the simultaneous intersection of these beams to extract a contained hot plasma (P), including a measured chemical element present in the targets and another chemical element exogenous to the targets and present in a known quantity on this medium; b) luminous emission rays for each plasma, corresponding to the quantified element and exogenous element, are detected and anglyset each measuring point while measuring the brightness of these rays; then c) the concentration in each measuring point of the quantified element is determined through prior calibration of the rays of the qualified element to determine a correlation between the brightness of the rays, specific to said element, and the concentrations the latter in mixtures of the quantified element and the exogenous element in known proportions. | 05-12-2011 |
Jean-Jacques Bosc, Pompignac FR
| Patent application number | Description | Published |
|---|---|---|
| 20110301187 | BIS [O-(14-BENZOYLACONINE-8-YL)] ESTERS - The present invention concerns novel compounds having the structure (I). Another object of the invention is the use of compounds (I) for the fabrication of a medicament which is used for the treatment of tumour diseases. | 12-08-2011 |
Nathalie Bosc, Montanay FR
| Patent application number | Description | Published |
|---|---|---|
| 20110196041 | Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate - The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments. | 08-11-2011 |